IP Library Granted Patent US 10,351,574
Granted Patent B2
US 10,351,574 · App. 15/730,885 · Granted Jul 16, 2019

Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,351,574
App. No.
15/730,885
Granted
Jul 16, 2019
Kind
B2
Abstract

Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.

Claims (6)

1. A compound comprising a polymorphic form of hydrocodone benzoic acid enol ester hydrochloride, wherein the polymorphic form is Form I, wherein Form I has an x-ray powder diffraction pattern comprising peaks at about the following 2θ values: 9.05, 12.32, 13.16, 14.94, and 18.57.

2. The compound of claim 1 , wherein Form I has an x-ray powder diffraction pattern further comprising peaks at about the following 2θ values: 6.16, 10.95, 11.91, 14.60, 17.04, 17.23, 17.80, 19.18, 20.66, 21.10, 22.15, 23.50, 26.07, and 28.39.

3. A solid pharmaceutical composition comprising a therapeutically effective amount of a polymorphic form of hydrocodone benzoic acid enol ester hydrochloride and a pharmaceutically acceptable excipient in a formulation for oral administration, wherein the polymorphic form is Form I, wherein Form I has an x-ray powder diffraction pattern comprising peaks at about the following 2θ values: 9.05, 12.32, 13.16, 14.94, and 18.57.

4. The solid pharmaceutical composition of claim 3 , wherein Form I has an x-ray powder diffraction pattern further comprising peaks at about the following 2θ values: 6.16, 10.95, 11.91, 14.60, 17.04, 17.23, 17.80, 19.18, 20.66, 21.10, 22.15, 23.50, 26.07, and 28.39.

5. A method for treating pain in a patient comprising the step of selecting a patient that is in need of pain treatment, administering to said patient a pharmaceutical composition comprising a therapeutically effective amount of one or more polymorphic forms of hydrocodone benzoic acid enol ester hydrochloride the compound of claim 1 .

6. A method for treating pain in a patient comprising the step of selecting a patient that is in need of pain treatment, administering to said patient a pharmaceutical composition comprising a therapeutically effective amount of one or more polymorphic forms of hydrocodone benzoic acid enol ester hydrochloride the compound of claim 3 .

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 13, 2026
From: ALTER DOMUS (US) LLC
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 075080/0907 →
SECURITY INTEREST Recorded Apr 8, 2024
From: ZEVRA THERAPEUTICS, INC.
To: ALTER DOMUS (US) LLC
Reel/Frame 067040/0637 →
CHANGE OF NAME Recorded Feb 23, 2024
From: KEMPHARM, INC.
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 066664/0108 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 048387 FRAME: 0656. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 25, 2019
From: MICKLE, TRAVIS; GUENTHER, SVEN; MICKLE, CHRISTAL; CHI, GUOCHEN; KANSKI, JAROSLAW; MARTIN, ANDREA K.; BERA, BINDU
To: KEMPHARM, INC.
Reel/Frame 048691/0373 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2019
From: MICKLE, TRAVIS; GUENTHER, SVEN; MICKLE, CHRISTAL; CHI, GUOCHEN; KANSKI, JAROSLAW; MARTIN, ANDREA K.; BERA, BINDU
To: KEMPHARM, INC.,
Reel/Frame 048387/0656 →